Press Release of Un-Audited Financual results - Q1FY27.
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 27 Jul 2026, 02:12 PM IST · BSE ID: 9430f5f5-7308-4c50-89a8-90033ea5ea55
View Original BSE Filing (PDF)
💡
In Simple Terms
Epigral's latest quarterly profit increased by 25%, and it announced a major ₹600 crore investment for new chemical manufacturing plants.
🤖 AI Summary
- Epigral's Q1 FY27 PAT increased 25% year-on-year to ₹ 99 Cr from ₹ 79 Cr in Q1 FY26.
- Quarterly revenue rose 15% year-on-year to ₹ 709 Cr in Q1 FY27 from ₹ 615 Cr in Q1 FY26.
- Board approved ₹600 Cr capex for a 1,25,000 TPA Epoxy Resin & Formulations plant and a Multi-Purpose Plant.
- New plants are expected to be commissioned in H2 FY28, with a pilot plant operational by Q2 FY27.
- Over 50% of raw material value for the new projects will be sourced internally.
- EBITDA grew 10% to ₹ 179 Cr with a 25% margin; ROCE stood at 16% in Q1 FY27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue Q1 FY27
₹ 709 Cr
15%
Total Capex Approved
₹600 crore
Epoxy Resin Plant Capacity
1,25,000 TPA
Absolute EBITDA Q1 FY27
₹ 179 Crore
10%
Absolute EBITDA Q1 FY26
₹ 163 Crore
EBITDA Margin Q1 FY27
25%
Net Debt/EBITDA as on 30th June 2026
0.8x
🏢 How This Affects the Company
The strategic expansion into Epoxy Resin & Formulations and a Multi-Purpose Plant marks Epigral's forward integration into advanced materials and specialty chemicals, broadening its product portfolio and market reach across various industrial segments. Internal sourcing of over 50% of raw materials for new projects leverages existing integrated manufacturing advantages.
The ₹600 crore capex commitment will impact the company's capital allocation and potentially increase debt or require internal accruals. The lower ROCE of 16% in Q1 FY27 compared to 24% in Q1 FY26 is partly attributed to a sizeable Capital Work in Progress, indicating ongoing investment impact.
The new plants will add 1,25,000 TPA capacity for Epoxy Resin & Formulations and a Multi-Purpose Plant for downstream ECH and Chlorotoluenes products, significantly increasing manufacturing output and diversifying production capabilities. A pilot plant will optimize manufacturing processes and facilitate customer approvals before commercial scale-up.
The substantial ₹600 crore capex introduces execution risks associated with large-scale projects, including potential delays, cost overruns, and market acceptance of new products. However, internal raw material sourcing mitigates supply chain risks for the new ventures.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results and capex announcement.
👤
Who Is Affected
Existing shareholders are affected by the company's financial performance in Q1 FY27 and its strategic direction with the approved ₹600 Cr capital expenditure.
🔍
Management Signal
Management is signaling a commitment to strategic expansion, product diversification into specialty chemicals, and leveraging integrated manufacturing for long-term value creation.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor progress on pilot plant commissioning and financial performance.
H2 FY28 plant commissioning — track updates on new Epoxy Resin and MPP facilities.
Future capex plans — observe announcements on funding and execution of the ₹600 crore project.
MEDIUM RISK
Execution risks associated with the ₹600 crore capex and potential impact on ROCE from capital work in progress.
💡 Investor Takeaway
Epigral reported a Q1 FY27 PAT of ₹ 99 Cr, up 25% year-on-year, and revenue of ₹ 709 Cr, up 15%. The company announced a ₹600 Cr capex for an Epoxy Resin and Multi-Purpose Plant, expected to commission in H2 FY28, strengthening forward integration.
⚖️ Strengths & Concerns
✅ Positives
- PAT increased 25% year-on-year to ₹ 99 Cr in Q1 FY27, demonstrating strong profit growth.
- Revenue grew 15% year-on-year to ₹ 709 Cr in Q1 FY27, supported by a 5% YoY sales volume growth.
⚠️ Concerns
- Return on Capital Employed (ROCE) decreased to 16% in Q1 FY27 from 24% in Q1 FY26, partly due to Capital Work in Progress.
- Despite revenue growth, EBITDA margin remained at 25% in Q1 FY27, showing a 10% absolute EBITDA growth versus a 15% revenue growth.
📅 Company Track Record
Previous filings indicated Epigral's Q1 FY26 standalone net profit was Rs. 99.18 Crore and a new subsidiary was incorporated. The board met on 27th July, 2026, to approve the Q1 FY27 results and other items. The current Q1 FY27 PAT is ₹ 99 Cr, compared to the previously reported Q1 FY26 PAT of ₹ 79 Cr in this press release.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Epigral Limited's net profit in Q1 FY27?
Epigral Limited reported a Profit After Tax (PAT) of ₹ 99 Cr for Q1 FY27, which is a 25% increase compared to ₹ 79 Cr in Q1 FY26.
What was Epigral Limited's revenue in Q1 FY27?
The company's revenue in Q1 FY27 stood at ₹ 709 Cr, marking a 15% growth from ₹ 615 Cr recorded in Q1 FY26.
What capital expenditure has Epigral Limited approved?
Epigral Limited's board approved an estimated capital expenditure of approximately ₹600 crore for an Epoxy Resin & Formulations plant and a Multi-Purpose Plant.
When are Epigral Limited's new plants expected to be commissioned?
The commercial Epoxy Resin & Formulations plant and the Multi-Purpose Plant are expected to be commissioned in H2 FY28, with a pilot plant operational by Q2 FY27.
What was Epigral Limited's EBITDA margin in Q1 FY27?
Epigral Limited's EBITDA margin stood at 25% in Q1 FY27, with absolute EBITDA growing 10% to ₹ 179 Crore from ₹ 163 Crore in Q1 FY26.
Questions based on this BSE filing only. For information purposes.